These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 17617664)

  • 1. Molecular targets for treating cognitive dysfunction in schizophrenia.
    Gray JA; Roth BL
    Schizophr Bull; 2007 Sep; 33(5):1100-19. PubMed ID: 17617664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006 Sep; 67(9):e11. PubMed ID: 17081078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.
    Buchanan RW; Freedman R; Javitt DC; Abi-Dargham A; Lieberman JA
    Schizophr Bull; 2007 Sep; 33(5):1120-30. PubMed ID: 17641146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular signaling and approaches to the treatment of schizophrenia and associated cognitive impairment.
    Snyder GL; Vanover KE
    Curr Pharm Des; 2014; 20(31):5093-103. PubMed ID: 24345266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating impaired cognition in schizophrenia.
    Ibrahim HM; Tamminga CA
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1587-94. PubMed ID: 22283754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review.
    Masana M; Santana N; Artigas F; Bortolozzi A
    Curr Top Med Chem; 2012; 12(21):2357-74. PubMed ID: 23279176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
    Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
    Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On the trail of a cognitive enhancer for the treatment of schizophrenia.
    Stip E; Chouinard S; Boulay LJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):219-32. PubMed ID: 15694228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
    Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
    Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.
    Coyle JT; Balu D; Benneyworth M; Basu A; Roseman A
    Dialogues Clin Neurosci; 2010; 12(3):359-82. PubMed ID: 20954431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic drug development.
    Kim DH; Stahl SM
    Curr Top Behav Neurosci; 2010; 4():123-39. PubMed ID: 21312399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating schizophrenia: novel targets for the cholinergic system.
    Money TT; Scarr E; Udawela M; Gibbons AS; Jeon WJ; Seo MS; Dean B
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):241-56. PubMed ID: 20053170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug targets for cognitive enhancement in neuropsychiatric disorders.
    Wallace TL; Ballard TM; Pouzet B; Riedel WJ; Wettstein JG
    Pharmacol Biochem Behav; 2011 Aug; 99(2):130-45. PubMed ID: 21463652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The search for novel antipsychotics: pharmacological and molecular targets.
    Sanger DJ
    Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia.
    Rajagopal L; Massey BW; Huang M; Oyamada Y; Meltzer HY
    Curr Pharm Des; 2014; 20(31):5104-14. PubMed ID: 24345269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.